Skip to main navigation

HOME
ABOUT ENZON
ROYALTY PRODUCTS
INVESTORS & MEDIA
Investor Relations
CONTACT US

Request Information
Email Alerts
Download Library
RSS News Feeds

Shareholder Tools

Downloads

Print

Downloads

Categories

Year

Sep 11, 2012

Enzon to Present at 2012 World Congress and Expo on Biowaivers and Biosimilars 13.3 KB

Aug 01, 2012

Enzon Reports Second Quarter 2012 Results 22.3 KB

Jul 16, 2012

Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting 65.9 KB

Jun 19, 2012

Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference 13.2 KB

Jun 04, 2012

Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting 14.2 KB

May 07, 2012

Enzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China 15.5 KB

May 02, 2012

Enzon Reports First Quarter 2012 Results 19.6 KB

Mar 12, 2012

Enzon Reports Fourth-Quarter and Full-Year 2011 Results 77.9 KB

Dec 08, 2011

Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer 14 KB

Nov 12, 2011

Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting 17.2 KB

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

©2025 Enzon Pharmaceuticals, Inc., All Rights Reserved.